Vivos Therapeutics updates Nasdaq compliance status after $7.5M private placement; hearing June 27

Vivos Therapeutics, Inc.

Received Nasdaq deficiency notice on May 16, 2024 for failing to meet $2.5M equity requirement.
Completed $7.5M private placement on June 10, 2024; believes it now meets equity requirement.
Hearing before Nasdaq Panel scheduled June 27, 2024; decision expected within 30 days.
Company acknowledges it will need additional equity capital to maintain ongoing compliance.
Risk of delisting if unable to demonstrate compliance; could materially affect stock price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.